Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study

Juan Pablo Alderuccio; Weiyun Z Ai; John Radford; Melhem M Solh; Kirit M Ardeshna; Matthew Lunning; Brian Hess; Pier Luigi Zinzani; Anastasios Stathis; Carmelo Carlo Stella; Mehdi Hamadani; Brad S Kahl; David Ungar; Turk Kilavuz; Eric Yu; Yajuan Gu Qin; Paolo F Caimi

doi:10.1182/bloodadvances.2022007782

Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study

Juan Pablo Alderuccio, Weiyun Z Ai, John Radford, Melhem M Solh, Kirit M Ardeshna, Matthew Lunning, Brian Hess, Pier Luigi Zinzani, Anastasios Stathis, Carmelo Carlo Stella, Mehdi Hamadani, Brad S Kahl, David Ungar, Turk Kilavuz, Eric Yu, Yajuan Gu Qin, Paolo F Caimi

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	4736-4739
Number of pages	4
Journal	Blood Advances
Volume	6
Issue number	16
DOIs	https://doi.org/10.1182/bloodadvances.2022007782
Publication status	Published - 16 Aug 2022

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1182/bloodadvances.2022007782

Cite this

Alderuccio, J. P., Ai, W. Z., Radford, J., Solh, M. M., Ardeshna, K. M., Lunning, M., Hess, B., Luigi Zinzani, P., Stathis, A., Carlo Stella, C., Hamadani, M., Kahl, B. S., Ungar, D., Kilavuz, T., Yu, E., Qin, Y. G., & Caimi, P. F. (2022). Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study. Blood Advances, 6(16), 4736-4739. https://doi.org/10.1182/bloodadvances.2022007782

@article{628c8d0a8afc49d8a00833b077d569ba,

title = "Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study",

author = "Alderuccio, {Juan Pablo} and Ai, {Weiyun Z} and John Radford and Solh, {Melhem M} and Ardeshna, {Kirit M} and Matthew Lunning and Brian Hess and {Luigi Zinzani}, Pier and Anastasios Stathis and {Carlo Stella}, Carmelo and Mehdi Hamadani and Kahl, {Brad S} and David Ungar and Turk Kilavuz and Eric Yu and Qin, {Yajuan Gu} and Caimi, {Paolo F}",

year = "2022",

month = aug,

day = "16",

doi = "10.1182/bloodadvances.2022007782",

language = "English",

volume = "6",

pages = "4736--4739",

journal = "Blood Advances",

issn = "2473-9537",

publisher = "American Society of Hematology",

number = "16",

}

Alderuccio, JP, Ai, WZ, Radford, J, Solh, MM, Ardeshna, KM, Lunning, M, Hess, B, Luigi Zinzani, P, Stathis, A, Carlo Stella, C, Hamadani, M, Kahl, BS, Ungar, D, Kilavuz, T, Yu, E, Qin, YG & Caimi, PF 2022, 'Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study', Blood Advances, vol. 6, no. 16, pp. 4736-4739. https://doi.org/10.1182/bloodadvances.2022007782

TY - JOUR

T1 - Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma

T2 - a subgroup analysis from the LOTIS-2 study

AU - Alderuccio, Juan Pablo

AU - Ai, Weiyun Z

AU - Radford, John

AU - Solh, Melhem M

AU - Ardeshna, Kirit M

AU - Lunning, Matthew

AU - Hess, Brian

AU - Luigi Zinzani, Pier

AU - Stathis, Anastasios

AU - Carlo Stella, Carmelo

AU - Hamadani, Mehdi

AU - Kahl, Brad S

AU - Ungar, David

AU - Kilavuz, Turk

AU - Yu, Eric

AU - Qin, Yajuan Gu

AU - Caimi, Paolo F

PY - 2022/8/16

Y1 - 2022/8/16

U2 - 10.1182/bloodadvances.2022007782

DO - 10.1182/bloodadvances.2022007782

M3 - Article

C2 - 35790100

SN - 2473-9537

VL - 6

SP - 4736

EP - 4739

JO - Blood Advances

JF - Blood Advances

IS - 16

ER -